设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 529|回复: 0

[共享] 癌症免疫疗法的嵌合抗原受体:最新研究与未来展望

[复制链接]
发表于 2015-8-27 10:48:49 | 显示全部楼层 |阅读模式
Chimericantigen receptor for adoptiveimmunotherapy of cancer: latest research andfutureprospect
癌症免疫疗法的嵌合抗原受体:最新研究与未来展望
Abstract:
Chimeric antigen receptors (CARs) arerecombinant receptors that combine the specificity of an antigen-specificantibody with the T-cell’s activating functions. Initial clinical trials ofgenetically engineered CAR T cells have significantly raised the profile of Tcell therapy, and great efforts have been made to improve this approach. Inthis review, we provide a structural overview of the development of CARtechnology and highlight areas that requirefurther refinement. We also discusscritical issues related to CAR therapy, including the optimization of CAR Tcells, the route of administration, CAR toxicity and the blocking of inhibitorymolecules.
摘要:
和大家分享一下老外的一篇关于CAR-T的综述,这份文件详细的叙述了嵌合抗原受体技术及其结构的演化过程,同时也讨论了嵌合抗原受体T细胞的治疗的关键因素,包括CAR-T细胞的优化,给药途径,细胞毒性以及在未来和免疫检查点分子合用的可能性等等。总之好文一份 ,欢迎大家下载哦

Chimeric antigen receptor for adoptive immunotherapy of cancer latest research a.pdf

841.26 KB, 下载次数: 255

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-1-23 20:32 , Processed in 0.109001 second(s), 27 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表